Introduction: Although prostate cancer (PCa) incidence is lower in HIV' men than in HIV( men, the usefulness of prostatespecific antigen (PSA) screening in this population is not well defined and may have higher false negative rates than in HIV ( men. We aimed to describe the kinetics and predictive value of PSA in HIV' men. Methods: Men with PCa (n021) and up to two matched controls (n 040) with prospectively stored plasma samples before PCa (or matched date in controls) were selected. Cases and controls were matched on date of first and last sample, age, region of residence and CD4 count at first sample date. Total PSA (tPSA), free PSA (fPSA), testosterone and sex hormone binding globulin (SHBG) were measured. Conditional logistic regression models investigated associations between markers and PCa. Sensitivity and specificity of using tPSA 4 mg/L to predict PCa was calculated. Mixed models were used to describe kinetics. Results: Sixty-one men were included with a median six (IQR 2Á9) years follow-up. Time between last sample and PCa was seven (4Á11) months. Cases and controls were well matched at first sample, with a median age of 51 (IQR 48Á57) and CD4 of 437 (243Á610) cells/mm . The most informative predictor of PCa was tPSA (AUC00.9), followed by fPSA (0.8). Testosterone (AUC 0 0.5) and SHBG (0.5) were poor predictors of PCa. Overall, tPSA level 4 mg/L had 99% specificity and 37% sensitivity. Performance was best in the year prior to PCa (specificity: 99%, sensitivity: 88%). Conclusions: PSA was highly predictive of PCa in HIV' men. Our results indicate that PSA screening in HIV' men may be useful, and further work is needed to identify potentially age-related cut-offs to maximize sensitivity and specificity to identify those for further evaluation at early stages of PCa.
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